Navicixizumab (Anti-DLL4 & VEGF)
Product Specifications
CAS Number
1638338-43-8
Synonyms
OMP 305B83
SKU
C00920-1mg
Target
VEGFR
Applications
Protein Tyrosine Kinase
Additionnal Information
Navicixizumab is a bispecific monoclonal antibody targeting DLL4 and VEGF, with potential anti-angiogenic and antineoplastic activities. It has shown antitumor effects in multiple cancer types, with the most promising results in ovarian cancer. M.W 146.17 kDa
Storage Conditions
-80°C (avoid freeze-thaw cycles)
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6385857-01 0.1 mL
MPZL2 (Myelin Protein Zero-like Protein 2, Epithelial V-like Antigen 1, EVA, EVA1, UNQ606/PRO1192) (MaxLight 405)
Ask
View Details 
MBS6385857-02 5x 0.1 mL
MPZL2 (Myelin Protein Zero-like Protein 2, Epithelial V-like Antigen 1, EVA, EVA1, UNQ606/PRO1192) (MaxLight 405)
Ask
View Details GTR15292097 1 Vial
Lentiviral mouse H2-Aa shRNA (UAS) - Lentiviral mouse H2-Aa shRNA (UAS) (25)
Ask
View Details 